Next generation sequencing identifies novel gene alterations with potential prognostic relevance in pediatric cancer: a single-center study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag147 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Yuhan Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology/Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Neuroblastoma, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangzhou Area Clinical Specialty Technology, Sun Yat-Sen Medical-industrial Integration Cultivating Program, Heilongjiang Harbin Yida Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
Next generation sequencing (NGS) has driven the development of precision oncology. While adult cancer genomics has been extensively studied, pediatric cancer, particularly among Asian populations, has received less attention.
Methods
We screened gene alteration profiles of 99 pediatric cancer patients using the targeted NGS panel and compared the results with those from Western cohorts. The relationship between genes and clinical characteristics was also analyzed.
Results
The most frequently mutated gene was KMT2D (18.2%), followed by TP53 (11.1%) and DICER1 (9.1%). The frequency of KMT2D mutations in our cohort is significantly higher than in Western cohorts, whereas TP53 mutations showed no significant difference. Pathogenic or likely pathogenic (P/LP) germline mutations were identified in only 3.5% of the patients. Notably, 69%-75% of patients had at least one genomic alteration with potential clinical significance. In neuroblastoma (NB), the most commonly altered genes were MYCN (7/48), DICER1 (6/48), ARID1B, EGFR, KMT2D, and TCF3 (5/48). In a subset of intermediate-/high-risk NB patients (n = 33), MYCN amplification was associated with disease progression during induction chemotherapy, and gene alterations in the MAPK pathway were associated with poor survival. We also identified novel alterations in specific tumor types, including SFPQ-TACC1 fusion in NB.
Conclusions
Our findings enhance understanding of the genomic landscape of Chinese pediatric cancer populations. Further research is required to validate these findings and fully explore the potential of genomic data to improve outcomes for pediatric cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology/Oncology, Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Head Neck and Thyroid Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008, Zhengzhou, China.
- Department of Pediatric Intensive Care Unit, Shenzhen Children's Hospital, 518026, Shenzhen, China.
ORCID-Profile: Yang Li
Förderung
- Guangzhou Area Clinical Specialty Technology
- Sun Yat-Sen Medical-industrial Integration Cultivating Program
- Heilongjiang Harbin Yida Pharmaceutical Co., Ltd
Zitieren
APA
Ma, Y., Su, M., Liu, X., Wang, W., Wu, Y., Wang, Z., Peng, X., Xiong, X., Lei, J., & Li, Y. (2026). Next generation sequencing identifies novel gene alterations with potential prognostic relevance in pediatric cancer: a single-center study. The Oncologist. https://doi.org/10.1093/oncolo/oyag147
Vancouver
Ma Y, Su M, Liu X, Wang W, Wu Y, Wang Z, et al. Next generation sequencing identifies novel gene alterations with potential prognostic relevance in pediatric cancer: a single-center study. The Oncologist. 2026. doi:10.1093/oncolo/oyag147
BibTeX
@article{Ma2026,
author = {Ma, Yuhan and Su, Mingwei and Liu, Xiaoshan and Wang, Wenxia and Wu, Yu and Wang, Zhixuan and Peng, Xiaomin and Xiong, Xilin and Lei, Jiaying and Li, Yang},
title = {Next generation sequencing identifies novel gene alterations with potential prognostic relevance in pediatric cancer: a single-center study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag147}
}
EUVIMED